Goldfinch Bio names Kuvalanka Chief Financial and Operating Officer, and promoted Lori Rudolph-Owen, to Chief Development Officer.
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Goldfinch Bio, a U.S.-based, clinical stage biotechnology company focused on discovering and developing precision medicines for the treatment of kidney disease, today announced the appointment of Kyle Kuvalanka as Chief Financial and Operating Officer and the promotion of Lori Rudolph-Owen, Ph.D., from Senior Vice President, R&D Strategy and Operations to Chief Development Officer, effective immediately.
“We are delighted to welcome Kyle as Chief Financial and Operating Officer,” said Anthony Johnson, M.D., President and Chief Executive Officer of Goldfinch Bio. “Throughout his career, Kyle has demonstrated an ability to successfully guide teams through significant organizational growth. I am confident that his extensive experience in both corporate and financial strategy will be of tremendous value as we build Goldfinch into an enduring company.”
Dr. Johnson said: “Lori’s promotion to Chief Development Officer reflects her many contributions driving GFB-887 through clinical development and GFB-024 towards an investigational new drug (IND) filing, as well as her success building Goldfinch’s R&D and regulatory strategy teams. I look forward to Lori’s continued partnership establishing Goldfinch as the leader in applying a precision medicine approach for the treatment of kidney diseases.”
Kyle Kuvalanka, Chief Financial and Operating Officer
Mr. Kuvalanka said: “Goldfinch was established on a commitment to revolutionize the treatment of kidney diseases by applying a genomics-based approach to drug discovery and development. Over the past twenty years, we have seen the value of precision medicine play out across oncology. By taking a similar approach and targeting the molecular causes of kidney disease, I believe Goldfinch has the potential to deliver tremendous benefit to patients, many of whom are underserved by existing therapeutic options.”
Lori Rudolph-Owen, Chief Development Officer
“I am honored to take on this new role at Goldfinch, particularly as we prepare to advance GFB-887 into Phase 2 studies this quarter,” said Dr. Rudolph-Owen. “Recent breakthroughs in genetics and biology have generated a new understanding of the key drivers of kidney disease, and I am excited to continue working with the talented and highly-productive Goldfinch team to translate these learnings into first-in-class therapies for patients in need.”